Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEIRAGTX HOLDINGS PLC

(MGTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
18.49(c) 16.97(c) 16.48(c) 15.76(c) 15.44 Last
196 110 234 392 171 974 160 991 199 204 Volume
-2.22% -8.22% -2.89% -4.37% -2.03% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 18,2 M - -
Net income 2021 -97,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,56x
Yield 2021 -
Sales 2022 24,5 M - -
Net income 2022 -102 M - -
Net Debt 2022 - - -
P/E ratio 2022 -7,92x
Yield 2022 -
Capitalization 701 M 701 M -
Capi. / Sales 2021 38,5x
Capi. / Sales 2022 28,6x
Nbr of Employees 271
Free-Float -
More Financials
Company
MeiraGTx Holdings plc is a clinical-stage gene therapy company. The Company develops gene therapy treatments for a range of inherited and acquired disorders. It is focused on developing therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia, radiation treatment for head and neck cancers and neurodegenerative diseases, such as amyothrophic lateral sclerosis (ALS). It is also... 
Sector
Pharmaceuticals
Calendar
03/29Earnings Release
More about the company
Ratings of MeiraGTx Holdings plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MEIRAGTX HOLDINGS PLC
2021MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation
GL
2021MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation
GL
2021MEIRAGTX : Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AA..
PU
2021MEIRAGTX HOLDINGS PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
2021MeiraGTx Holdings Reports Positive Preliminary Data From Trial of Potential Treatment f..
MT
2021MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of A..
AQ
2021MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of A..
CI
2021MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research an..
AQ
2021MeiraGTx Holdings Q3 Loss Deepens, Revenue Rises
MT
2021MEIRAGTX HOLDINGS PLC Management's Discussion and Analysis of Financial Condition and ..
AQ
2021MeiraGTx Reports Third Quarter 2021 Financial and Operational Results - Form 8-K
PU
2021MeiraGTx Reports Third Quarter 2021 Financial and Operational Results
AQ
2021MeiraGTx to Participate in Upcoming Virtual Investor Conferences
AQ
2021INSIDER SELL : Meiragtx Holdings
MT
2021MEIRAGTX : Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Program..
AQ
More news
News in other languages on MEIRAGTX HOLDINGS PLC
2021MeiraGTx Holdings annonce des données préliminaires positives sur l'essai d'un traiteme..
2021La perte de MeiraGTx Holdings au troisième trimestre s'accentue, mais les recettes augm..
2021VENTE D'INITIÉS : Meiragtx Holdings
2021MeiraGTx enregistre une perte plus importante au premier trimestre, mais ses revenus s'..
2021La perte de MeiraGTx pour l'ensemble de l'année 2020 se réduit en raison de l'augmentat..
More news
Analyst Recommendations on MEIRAGTX HOLDINGS PLC
More recommendations
Chart MEIRAGTX HOLDINGS PLC
Duration : Period :
MeiraGTx Holdings plc Technical Analysis Chart | MGTX | KYG596651029 | MarketScreener
Technical analysis trends MEIRAGTX HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 15,76 $
Average target price 37,14 $
Spread / Average Target 136%
EPS Revisions
Managers and Directors
Alexandria Forbes President, Chief Executive Officer & Director
Richard Giroux Chief Operating & Financial Officer
Keith Reginald Harris Director
Robert K. Zeldin Chief Medical Officer
Ellen Hukkelhoven Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MEIRAGTX HOLDINGS PLC-33.61%701
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833